Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference
Rhea-AI Summary
Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotechnology company focused on precision cancer medicines, has announced its participation in the upcoming Guggenheim SMID Cap Biotechnology Conference. Barbara Weber, M.D., the company's President and CEO, will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 10:00 AM ET.
The event will be accessible through a live webcast, available at the provided link and through the company's website under the 'Events & Presentations' section of the Investors page. The presentation recording will remain available on Tango's website for 90 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, TNGX declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim SMID Cap Biotechnology Conference on Wednesday, February 5, 2025 at 10:00 AM ET.
A live webcast of the fireside chat can be accessed at https://wsw.com/webcast/guggen2/tngx/2036463 and will be available under the "Events & Presentations" tab on the “Investors” page on the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Tango Therapeutics
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.
Investor Contact:
Daniella Beckman
Chief Financial Officer, Tango Therapeutics
IR@tangotx.com
Media Contact:
Daniella Beckman
Chief Financial Officer, Tango Therapeutics
media@tangotx.com
Source: Tango Therapeutics, Inc.
FAQ
When is Tango Therapeutics (TNGX) presenting at the Guggenheim SMID Cap Biotechnology Conference 2025?
How can investors watch Tango Therapeutics' (TNGX) Guggenheim Conference presentation?
How long will Tango Therapeutics' (TNGX) Guggenheim Conference presentation be available for replay?
Who will represent Tango Therapeutics (TNGX) at the Guggenheim SMID Cap Biotechnology Conference?
